The Omicron variant took hold of the fears of people all around the world when it emerged. While it didn’t spark the same level of panic that the coronavirus itself lent, it nevertheless took on its own version of that. And just like there was a large request for a vaccine the first time around, so too was the case for Omicron.

Moderna, the company responsible for making one of the more popular and supposedly effective COVID-19 vaccines, has worked tirelessly to try and roll out the Omicron variant. After lab reports showed that it had brought about a “strong immune response” in test subjects, the UK was the first country to jump on board.

“The first generation of COVID-19 vaccines being used in the UK continue to provide important protection against the disease and save lives,” June Raine, the Chief Executive of MHRA, said in a statement.

Raine continued: “What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.”

The post UK First to Approve Moderna Omicron Vaccine appeared first on theprimarymarket.com.

Thankfully, the pandemic that we’ll all remember for years to come has simmered down as of late. Many believe that this is thanks to the vaccines that were made for the virus—with a large portion of them being made and distributed by none other than pharmaceutical giant Moderna.

However, just because COVID-19 has slowed down doesn’t mean that we’re out of the woods. Other viruses have now taken up the mantel for the scariest viral bully in the playground, with the latest one sporting an intimidating name of Monkeypox.

But if you ask Moderna CEO Stéphane Bancel how he feels about it, he’ll tell you that this virus isn’t as serious as COVID-19 was. They’re working on a vaccine for it, but it’s not as pressing as other more dangerous threats.

“We don’t have the urgency we had when COVID happened,” said Bancel. “Because as you know, there is already a vaccine on the market.”

The reason that there’s already a vaccine for monkeypox is that it’s actually been around for five years, unbeknownst to many, in Africa. Bavarian Nordic, a Denmark-based company, is the maker of the vaccine.

Although other companies are working hard to make their own version of the monkeypox vaccine, Bancel’s statement leads us to believe that perhaps they’re not losing sleep over it just yet.

The post Moderna Says Monkeypox Not As Urgent as COVID-19 appeared first on theprimarymarket.com.

The Omicron variant took hold of the fears of people all around the world when it emerged. While it didn’t spark the same level of panic that the coronavirus itself lent, it nevertheless took on its own version of that. And just like there was a large request for a vaccine the first time around, so too was the case for Omicron.

Moderna, the company responsible for making one of the more popular and supposedly effective COVID-19 vaccines, has worked tirelessly to try and roll out the Omicron variant. After lab reports showed that it had brought about a “strong immune response” in test subjects, the UK was the first country to jump on board.

“The first generation of COVID-19 vaccines being used in the UK continue to provide important protection against the disease and save lives,” June Raine, the Chief Executive of MHRA, said in a statement.

Raine continued: “What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.”

The post UK First to Approve Moderna Omicron Vaccine appeared first on theprimarymarket.com.

Thankfully, the pandemic that we’ll all remember for years to come has simmered down as of late. Many believe that this is thanks to the vaccines that were made for the virus—with a large portion of them being made and distributed by none other than pharmaceutical giant Moderna.

However, just because COVID-19 has slowed down doesn’t mean that we’re out of the woods. Other viruses have now taken up the mantel for the scariest viral bully in the playground, with the latest one sporting an intimidating name of Monkeypox.

But if you ask Moderna CEO Stéphane Bancel how he feels about it, he’ll tell you that this virus isn’t as serious as COVID-19 was. They’re working on a vaccine for it, but it’s not as pressing as other more dangerous threats.

“We don’t have the urgency we had when COVID happened,” said Bancel. “Because as you know, there is already a vaccine on the market.”

The reason that there’s already a vaccine for monkeypox is that it’s actually been around for five years, unbeknownst to many, in Africa. Bavarian Nordic, a Denmark-based company, is the maker of the vaccine.

Although other companies are working hard to make their own version of the monkeypox vaccine, Bancel’s statement leads us to believe that perhaps they’re not losing sleep over it just yet.

The post Moderna Says Monkeypox Not As Urgent as COVID-19 appeared first on theprimarymarket.com.